The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Chugai Grants JW Pharmaceutical Marketing Rights for Emicizumab in South Korea
May 12, 2017
- Astellas, Univ. of Tokyo to Expand Research Collaboration on Rice-Based Oral Vaccine
May 12, 2017
- Baxalta Files Patent Infringement Lawsuit against Chugai over Development of Hemophilia A Treatment Emicizumab in US
May 12, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber
May 11, 2017
- Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
May 11, 2017
- Shionogi Wants to Zero In on Innovative Drugs, Teshirogi says on LLP Transfer
May 11, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
- Eisai Plans Japan Filing for Lenvima’s HCC Indication in June: CEO
May 11, 2017
- Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
May 11, 2017
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
- Fujifilm Invests 170 Million Yen in Regenerative Medicine Startup
May 11, 2017
- Takeda, UK Bioventure GammaDelta Pair Up for Development of New Immunotherapies Based on T cells
May 11, 2017
- Sales Rep Survey - 2: Drug Makers Exploring New Values amid Shift to Community-Based Care
May 10, 2017
- Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
- Takeda Calls off Hib Vaccine Launch on GSK’s Production Exit
May 10, 2017
- Japanese Drug Production Could Shrink to 6.8 Trillion Yen in 2024: Yano Research Institute
May 10, 2017
- BIKEN, Mitsubishi Tanabe Reach Final Agreement on Vaccine Joint Venture Slated to Begin Operation in September
May 10, 2017
- Daiichi Sankyo Starts Edoxaban Clinical Study in AF Patients following TAVI
May 10, 2017
- Eisai Suffers Setback in US Patent Litigation over Aloxi
May 9, 2017
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…